Blog

Physician’s take: If you’re price-shopping GLP-1s, you’re not alone — it’s the most common question we get. The pricing landscape is genuinely confusing: the same drug can cost $25 or $1,300 depending on your insurance. Here’s how to navigate it. Why coverage varies so much GLP-1s sit at the collision point of two different insurance […]

Physician’s take: The goal was never just “lose weight” — it’s lose fat while keeping muscle. With GLP-1s suppressing appetite so effectively, patients can undereat protein without realizing it. That’s a solvable problem, but only if someone’s watching for it. Why muscle loss happens Any rapid weight loss costs some lean mass — this isn’t

Physician’s take: Weight regain after stopping GLP-1s isn’t a personal failure — it’s predictable biology. Trials show most patients regain a large share of lost weight within a year of stopping. The fix isn’t willpower; it’s treating obesity as the chronic condition it is. Your body defends its weight Here’s the uncomfortable truth about weight

Physician’s take: Four famous brand names, two actual drugs. Understanding which is which matters — for your treatment, your dosing, and especially your insurance coverage. Two drugs, four brands Here’s the entire landscape in one table: Brand Active ingredient FDA-approved for Ozempic Semaglutide Type 2 diabetes Wegovy Semaglutide Chronic weight management Mounjaro Tirzepatide Type 2

Physician’s take: In head-to-head trials, tirzepatide produced more average weight loss than semaglutide — but “more effective on average” is not the same as “right for you.” Tolerability, medical history, and cost matter just as much. The short version Both medications are once-weekly injections that mimic gut hormones to reduce appetite. The key difference: Semaglutide

A 2026 randomized trial suggests that diets guided by food-sensitivity testing may outperform generic elimination diets for irritable bowel syndrome — with a few important caveats. What the study found A double-blind, sham-controlled trial from Sheba Medical Center, published in Gastroenterology Report (2026), looked at 68 patients with IBS (diarrhea-predominant or mixed type) enrolled between